Disease relevance of NSC35191

• N,N-dimethylacrylamide, a non-neurotoxic analogue, produced only body weight loss at this stage [1].

High impact information on NSC35191

• Copolymers of acrylamide (AM) and N,N-dimethylacrylamide (DMA) with AM to DMA molar ratios of 3:1, 2:1 and 1:1 and molecular weights of about 2.2 MDa were synthesized [2].
• Totally synthetic polymer with lectin-like function: induction of killer cells by the copolymer of 3-acrylamidophenylboronic acid with N,N-dimethylacrylamide [3].
• Artificial extracellular matrices were constituted of photocrosslinkable copolymers of N,N-dimethylacrylamide and 2-(7-coumaroxy)ethyl methacrylate; a copolymer with a high content of coumarin (A) was used as a basement membrane (BM) for the epithelium, and a copolymer with a low content (B) was used for entrapment of keratocytes [4].
• N,N-dimethylacrylamide produced inhibition of GAPDH as well as body weight loss without neuropathy [1].
• Enhanced protein solubility was achieved by cysteine blocking using both N,N-dimethylacrylamide (DMA) alkylation and bis(2-hydroxyethyl) disulphide (HED); an alternative procedure for the effective application of HED is demonstrated [5].

Biological context of NSC35191

• The synthesized monomer was copolymerized with N,N-dimethylacrylamide (DMAA) (molar ratio 1:3) and submitted to exhaustive phosphorylation [6].

Analytical, diagnostic and therapeutic context of NSC35191

• Surface behavior and molecular recognition in DNA microarrays from n,n-dimethylacrylamide terpolymers with activated esters as linking groups [7].

References